Clinical trials: Prostaglandins
Pregnancy, Premature Rupture of Membranes
Cervical Ripening in Premature Rupture of Membranes
Premature rupture of membranes (PROM) is diagnosed by demonstrating amniotic fluid in the vaginal canal before the onset of labor.
- Conditions
- Pregnancy, Premature Rupture of Membranes, Preterm Premature Rupture of Membranes, Unfavorable Cervix
- Trial name
- NCT02314728
- Testing
- Misoprostol, Oxytocin
- Where
- United States
- Volunteers
- 230 people, healthy volunteers welcome
- Sponsor
- Montefiore Medical Center
Induction of Labor Affected Fetus / Newborn
A Trial of Cervidil for Outpatient Pre-induction of Cervical Ripening
Induction of labor is a frequently planned obstetric procedure. Induction for women with an unfavorable cervix (bishop score <6) increases the risk of cesarean section.
- Trial name
- NCT03806231
- Testing
- Outpatient Dinoprostone 10mg, Inpatient Dinoprostone 10 mg
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Intermountain Health Care, Inc.
Labor Induction
Foley Catheter Versus Cervidil for Induction of Labor at Term
OBJECTIVE: To assess the efficacy of transcervical Foley catheter compared to controlled release prostaglandin (Cervidil™) for cervical ripening in term and near term women presenting for labor induction.
- Trial name
- NCT01402050
- Testing
- CERVIDIL (Dinoprostone), FOLEY BALLOON
- Where
- 2 sites in United States
- Volunteers
- 376 people, healthy volunteers welcome
- Sponsor
- Pediatrix
Healthy
Variability in Response to Non-steroidal Anti-inflammatory Drugs
This research study will evaluate inter-individual variability in the response to the non-steroidal anti-inflammatory drugs (NSAIDs), celecoxib and naproxen, among healthy adults.
- Trial name
- NCT02502006
- Testing
- Celecoxib, Naproxen
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- University of Pennsylvania
Emphysema
Prostaglandin Inhibition for Emphysema
The Prostaglandin Inhibition for Emphysema (PIE) study will determine if a currently available therapy, ibuprofen 600 mg three times daily, can block PGE production in the lower respiratory tract and if this results in…
- Trial name
- PIE (NCT02006576)
- Testing
- 600 mg ibuprofen three times daily for 48 weeks
- Where
- 5 sites in United States
- Volunteers
- 118 people, healthy volunteers welcome
- Sponsor
- University of Nebraska
Myocardial Infarction, Arthritis
Mechanisms of Action of Acetaminophen
This research study investigates whether the ability of aspirin to reduce the risk of heart attacks may be diminished by the administration of acetaminophen.
- Trial name
- NCT00646906
- Testing
- Aspirin First, Aspirin Last, Acetaminophen 1000 mg/d
- Where
- United States
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- University of Pennsylvania
Cataracts
A Comparison of Prostaglandin E2 (PGE2) Inhibition of Acuvail(Ketorolac 0.45%), Xibrom (Bromfenac 0.09%)and Nevanac (Nepafenac)in Patients Undergoing Phacoemulsification
Approximately 126 subjects scheduled to undergo cataract surgery by phacoemulsification, will be randomized in an even allocation (1:1:1) to either Acuvail, Xibrom or Nevanac.
- Trial name
- NCT01021761
- Testing
- Ketorolac Tromethamine, Bromfenac, nepafenac
- Volunteers
- 126 people, healthy volunteers welcome
- Sponsor
- Frank A. Bucci, Jr., M.D.
Type 2 Diabetes Mellitus
A Study to Evaluate the Effects of ER Niacin/Laropiprant, Laropiprant, ER Niacin, and Placebo on Urinary Prostanoid Metabolites (0524A-079)(COMPLETED)
The purpose of this study is to evaluate the potential effects of ER niacin/laropiprant, ER niacin, laropiprant, and placebo over the course of seven days on urinary levels of a specific metabolite (which is a marker of in vivo…
- Trial name
- NCT00618995
- Testing
- Comparator: ER niacin (+) laropiprant, Comparator: ER niacin, Comparator: laropiprant
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Hypercholesterolemia
A Study to Evaluate the Effects of Extended Release (ER) Niacin/Laropiprant, Laropiprant, ER Niacin, and Placebo on Urinary Prostanoid Metabolites in Subjects With High Cholesterol (0524A-075)(COMPLETED)
The purpose of this study is to evaluate the potential effects of ER niacin/laropiprant, ER niacin, laropiprant, and placebo over the course of seven days on urinary levels of a metabolite of thromboxane A2 (TxA2), as a marker of…
- Trial name
- NCT00769132
- Testing
- Comparator: niacin + laropiprant, Comparator: niacin, Comparator: laropiprant
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Nail Growth Cessation, Intraocular Pressure
Cutaneous Prostaglandin Application: Nail Growth, Nail Brittleness, and Eye Pressure
Topical prostaglandin agents are used to help reduce eye pressure in glaucoma patients. Bimatoprost (Lumigan 0.01%) is such an agent (Allergan, Inc.).
- Trial name
- NCT02448043
- Testing
- Bimatoprost 0.01%
- Where
- United States
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Northwestern University
Hyperlipidemia
Biosynthesis of PGD2 in Vivo
The investigator would like to see if aspirin could block niacin-induced flushing by analyzing blood and urine after taking aspirin. Phase I: Subjects were assigned to either placebo or aspirin groups.
- Trial name
- NCT01275300
- Testing
- Aspirin, Niacin
- Where
- United States
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- University of Pennsylvania
Hypertrichosis
Eyelash Growth From Application of Bimatoprost in Gel Suspension to the Base of the Eyelashes
Objective: To determine if Lumigan (bimatoprost) causes increased lash length when used in gel suspension applied to the base of the eyelashes.
- Trial name
- NCT00773136
- Testing
- Bimatoprost Suspension
- Where
- United States
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- University of Miami
Glaucoma
Safety and Tolerability of the Ophthalmic Solution PRO-179 Compared With Travatan®
Phase I clinical study, to evaluate the safety and tolerability of the ophthalmic solution PRO-179 compared with Travatan®, on the ocular surface of clinically healthy subjects.
- Trial name
- PRO-179/I (NCT03965052)
- Testing
- PRO 179, Travatan 0.004 % Ophthalmic Solution
- Where
- Mexico
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Laboratorios Sophia S.A de C.V.
Ovulation (Follicular Rupture Yes/no), Menstrual Cycles (Total Length, Bleeding Days)
The Effects of a Prostaglandin Inhibitor on Ovulation and the Menstrual Cycle
The investigators propose to test the hypothesis that the use of a prostaglandin inhibitor will result in premature luteolysis (ovulation failure) in women.
- Conditions
- Ovulation (Follicular Rupture Yes/no), Menstrual Cycles (Total Length, Bleeding Days), Gonadotropin and Ovarian Hormone Levels (FSH, LH, E2, P)
- Trial name
- NCT00614406
- Testing
- Celebrex
- Where
- United States
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- Oregon Health and Science University